Company · ALPMY
Astellas
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
27
15 still marketed
Novel approvals
15
Approvals since 2021
23
Originals and new uses
Phase 3 trials
175
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Xtandi new use Jul 24, 2026
- Xtandi new use Jul 24, 2026
- Padcev new use Priority reviewJul 10, 2026
- Padcev new use Priority reviewNov 21, 2025
- Vyloy new use OrphanJun 6, 2025
- Izervay new use Feb 12, 2025
- Vyloy approved NovelPriority reviewOrphanOct 18, 2024
- Padcev new use Priority reviewDec 15, 2023
- Padcev new use Priority reviewDec 15, 2023
- Cresemba new use Priority reviewOrphanDec 8, 2023
Drugs in development (13)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- folinic acidPhase 34 trials
Astellas · Unresectable Metastatic Colorectal Cancer, Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
- pudexacianinium chlorideASP5354Phase 32 trials
Astellas · Intraoperative Ureter Visualization, Abdominolpelvic Surgery
- RoxadustatFG-4592, ASP1517Phase 32 trials
Astellas · Chronic Kidney Disease, Renal Anemia, Myelodysplastic Syndromes
- SetidegrasibASP3082Phase 32 trials
Astellas · Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- ASP2138Phase 31 trial
Astellas · Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
- XNW27011ASP546CPhase 22 trials
Astellas · Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic
- ASP2246Phase 21 trial
Astellas · Chronic Ischemic Stroke
- ASP2767Phase 21 trial
Astellas · Glaucoma
- ASP2957MyoAAV3.8 engineered capsid - myosin heavy chain kinase 7 - human myotubularin, MyoAAV3.8-MHCK7-hMTM1Phase 21 trial
Astellas · X-linked Myotubular Myopathy
- ASP2998Phase 21 trial
Astellas · Locally Advanced or Metastatic Malignant Solid Tumors
- ASP388BPhase 21 trial
Astellas · Locally Advanced or Metastatic Solid Tumors
- ASP5541PRL-02Phase 21 trial
Astellas · Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
- Tacrolimus prolonged releasePhase 21 trial
Astellas · Intestine Transplantation, Kidney Transplantation, Lung Transplantation
Recruiting Phase 3 trials
Largest first.
- A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic CancerPivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07409272 · 614 participants (planned) · Start Feb 17, 2026 · Primary completion Aug 31, 2029
Drug: Setidegrasib; Oxaliplatin and 5 more · For: Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma
Sites: Gilbert, Arizona; Tucson, Arizona; Fort Smith, Arkansas · 104 sites in all
- A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric CancerPivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07673887 · 570 participants (planned) · Start Jul 28, 2026 · Primary completion Feb 28, 2031
Drug: ASP2138; Pembrolizumab and 6 more · For: Gastric Adenocarcinoma; Gastroesophageal Junction (GEJ) Adenocarcinoma
Sites: Saint Louis Park, Minnesota; Guangzhou, China; Kashiwa, Japan · 12 sites in all
- A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerPivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT06901531 · 500 participants (planned) · Start May 22, 2025 · Primary completion Sep 30, 2028
Drug: zolbetuximab; Pembrolizumab and 5 more · For: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer; Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer; Metastatic Gastric Adenocarcinoma or Cancer and 1 more
Sites: Birmingham, Alabama; Bakersfield, California; Cerritos, California · 253 sites in all
- Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)Pivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07566156 · 390 participants (planned) · Start May 11, 2026 · Primary completion Mar 31, 2030
Drug: Enfortumab vedotin; Cisplatin and 4 more · For: Urothelial Cancer; Urinary Bladder Neoplasms
Sites: Little Rock, Arkansas; Santa Barbara, California; Aurora, Colorado · 37 sites in all
- A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D MutationPivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07566052 · 356 participants (planned) · Start Aug 19, 2026 · Primary completion Jun 30, 2030
Drug: Setidegrasib; Docetaxel · For: Non-small Cell Lung Cancer (NSCLC)
Sites: Glendale, California; Los Angeles, California; San Francisco, California · 30 sites in all
- A Study to Confirm if Fezolinetant Helps to Reduce Hot Flashes in Indian Women Going Through MenopausePivotal-lookingRecruiting
Astellas Pharma IncAstellas (ALPMY)
NCT07829653 · 100 participants (planned) · Start Oct 23, 2026 · Primary completion Mar 31, 2028
Drug: Fezolinetant · For: Hot Flashes
Sites: Bengaluru, India
Marketed drugs (15)
Newest FDA action first.
- Xtandi Enzalutamide · 2020
- Xtandi Enzalutamide · 2012
- Padcev Enfortumab Vedotin-Ejfv · 2019
- Izervay Avacincaptad Pegol Sodium · 2023
- Vyloy Zolbetuximab-Clzb · 2024
- Cresemba Isavuconazonium Sulfate · 2015
- Cresemba Isavuconazonium Sulfate · 2015
- Veozah Fezolinetant · 2023
- Ambisome Amphotericin B · 1997
- Prograf Tacrolimus · 2018
- Prograf Tacrolimus · 1994
- Astagraf Xl Tacrolimus · 2013
- Prograf Tacrolimus · 1994
- Xospata Gilteritinib Fumarate · 2018
- Lexiscan Regadenoson · 2008
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.